Biomedicine · uk
Searching 80,000 Blood Samples for Early Signs of Brain Disease: UK Biobank Launches Neurodegeneration Protein Study
Blood stored for years may hold molecular clues from before a disease diagnosis. UKB-PRISM will measure hundreds of proteins to explore early changes in Alzheimer’s and Parkinson’s diseases; whether these can become reliable predictive tools awaits research validation.
By the time changes in memory or movement begin to appear, could clues already be present in the blood? The newly launched UKB-PRISM study will seek answers in 80,000 blood samples stored by UK Biobank, tracing protein changes that may occur before symptoms of neurodegenerative diseases emerge.
Alamar Biosciences and Nightingale Health announced the collaboration on November 2. The study will use Alamar’s NULISA platform at Nightingale’s laboratory to measure hundreds of circulating proteins. It covers Alzheimer’s disease, Parkinson’s disease and rare dementias, and is expected to be completed by the end of 2027. The announcement outlines the study’s launch plans; no disease prediction results are available yet.
One technical challenge is that some relevant proteins occur at extremely low levels in blood and can easily be obscured by background signals. According to Genetic Engineering & Biotechnology News, NULISA uses DNA-tagged antibodies to identify target proteins, reduces background interference through capture and release steps, and then reads the signals through sequencing. This gives researchers an opportunity to search large numbers of samples for subtle changes that were previously difficult to measure consistently.
The study’s value also lies in when the blood was collected. These stored samples allow scientists to look back at the molecular state of some participants years before diagnosis and compare it with subsequent health records to explore which protein changes appeared earlier. Combining these findings with imaging, genetic and lifestyle data may also help clarify relationships among different clues, rather than simply comparing people with and without disease at a single point in time.
Nightingale said it has generated metabolomic data for all 500,000 UK Biobank participants; the protein measurements will add another layer of molecular information to a subset of those samples. Funders include Alzheimer’s Research UK and LifeArc; reports on the same announcement by GEN and Longevity.Technology also list the Michael J. Fox Foundation, which supports Parkinson’s disease research. The involvement of research organizations focused on different diseases reflects the potential for this resource to support research into multiple brain diseases.
There is still a gap between measuring proteins and reliably predicting disease. Even if signals associated with later disease onset are identified, that would not directly prove they cause the disease, nor would it be sufficient to establish clinical screening. The announcement has not provided predictive accuracy figures for candidate markers, thresholds for clinical use or independent validation results. Future work must also test whether these signals can be reproduced in other populations.
Under current plans, once the study is completed, the full dataset will be made available to approved researchers worldwide through the UK Biobank Research Analysis Platform. The nearer-term outcome will be a research resource for cross-analysis: helping identify early disease clues and frame more specific questions for subsequent mechanistic research and clinical trial design. Whether it can bring diagnosis or intervention forward will depend on the analyses and validation that follow.